Diagnosis and management of inflammatory bowel disease in children.
Upwards of 100,000 children and adolescents are affected by inflammatory bowel disease (IBD) in the United States, and the incidence of IBD appears to be increasing worldwide. Although the diagnosis and differentiation of Crohn's disease or ulcerative colitis is still based on clinical, radiographic, endoscopic, and histological findings, newer less invasive serological tests are being employed to help distinguish these disorders and provide prognostic information to possibly guide therapy. Videocapsule endoscopy has increased our ability to detect previously unrecognized small bowel inflammation in selected patients. Whereas initial therapy has historically included aminosalicylates and corticosteroids, recent data suggest the limited efficacy of aminosalicylates in Crohn's disease and the high likelihood or corticosteroid dependence in patients with either Crohn's disease or ulcerative colitis. The early use of immunomodulators has become standard-of-care in both disorders and has decreased corticosteroid dependence. The advent of biologic therapy, primarily with infliximab, has dramatically improved short-term outcomes in both Crohn's disease and ulcerative colitis. Longer-term data on whether infliximab changes the natural history of these disorders (eg, requirement for surgery) awaits further study. As more aggressive therapy is being increasingly employed, rare complications such as lymphoma or opportunistic infection have developed.
Carvalho
Ryan
R
Children's Medical Center, Wright University and Boonshoft School of Medicine, Dayton, Ohio, USA.
Hyams
Jeffrey S
JS
D015415:Biomarkers / Q000097:blood; D053704:Capsule Endoscopy; D002648:Child; D003093:Colitis, Ulcerative / Q000175:diagnosis* / Q000628:therapy; D003424:Crohn Disease / Q000175:diagnosis* / Q000628:therapy; D003952:Diagnostic Imaging; D016099:Endoscopy, Gastrointestinal; D006801:Humans; D016896:Treatment Outcome
D015415:Biomarkers